Levemir

Peripheral insulin resistance is a key component of metabolic syndrome associated with obesity, dyslipidemia, hypertension, and… (More)

AIMS The aim of this analysis is to determine the timing of insulin initiation in routine clinical practice, especially in… (More)

A 52-year-old insulin-dependant diabetic man presented to the Emergency Department 2 hours after a deliberate massive overdose of… (More)

There is an association between insulin analogues, glargine, lispro and aspart and the incidence of malignancies. A 76 year-old… (More)

OBJECTIVE To discuss the design and baseline data of the Lantus (sanofi-aventis, Paris, France) versus Levemir (Novo Nordisk A/S… (More)

OBJECTIVE This study was conducted to quantify the long-term cost-effectiveness of insulin detemir (Levemir) versus intermediate… (More)

The search for target analytes to uncover the misuse of long acting insulin analogues (Lantus, Insulin Glargine; Levemir, Insulin… (More)

Forty-three case reports of patients with type 2 diabetes who were treated with insulin detemir (Levemir, Novo Nordisk A/S… (More)

Insulin detemir (Levemir) is a soluble long-acting human insulin analogue acylated with a 14-carbon fatty acid. Insulin detemir… (More)

Insulin detemir (Levemir) is a soluble long acting human insulin analogue acylated with a 14-carbon fatty acid. The fatty acid… (More)